Platelets From a Patient Heterozygous for the Defect of P2CYC Receptors for ADP Have a Secretion Defect Despite Normal Thromboxane A2 Production and Normal Granule …

M Cattaneo, A Lecchi, R Lombardi… - … , and vascular biology, 2000 - Am Heart Assoc
M Cattaneo, A Lecchi, R Lombardi, C Gachet, ML Zighetti
Arteriosclerosis, thrombosis, and vascular biology, 2000Am Heart Assoc
Two unrelated patients with a congenital bleeding diathesis associated with a severe defect
of the platelet ADP receptor coupled to adenylate cyclase (P2CYC) have been described so
far. In one of them, platelet secretion was shown to be abnormal. We recently showed that
platelets with the primary secretion defect (PSD; characterized by abnormal secretion but
normal granule stores, thromboxane A2 production, and ADP-induced primary wave of
aggregation) have a moderate defect of P2CYC. Therefore, the interaction of ADP with the …
Abstract
—Two unrelated patients with a congenital bleeding diathesis associated with a severe defect of the platelet ADP receptor coupled to adenylate cyclase (P2CYC) have been described so far. In one of them, platelet secretion was shown to be abnormal. We recently showed that platelets with the primary secretion defect (PSD; characterized by abnormal secretion but normal granule stores, thromboxane A2 production, and ADP-induced primary wave of aggregation) have a moderate defect of P2CYC. Therefore, the interaction of ADP with the full complement of its receptors seems to be essential for normal platelet secretion, and PSD patients may be heterozygotes for the congenital severe defect of P2CYC. In this study, we describe 2 new related patients with a severe defect of P2CYC and the son of one of them, who is to be considered an obligate heterozygote for the defect. The 2 patients with the severe defect had lifelong histories of abnormal bleeding, prolonged bleeding times, abnormalities of platelet aggregation and secretion, lack of inhibition of adenylate cyclase by ADP, and a deficiency of platelet-binding sites for [33P]2 MeS-ADP (240 and 225 sites per platelet; normal range, 530 to 1102). The son of one of them had a mildly prolonged bleeding time and abnormalities of platelet aggregation and secretion similar to those found in patients with PSD. In addition, his platelets showed a moderate defect of binding sites for [33P]2 MeS-ADP (430 sites per platelet) and of adenylate cyclase inhibition by ADP. This study of a family with the platelet disorder characterized by a defect of the platelet P2CYC receptor supports our hypothesis that the full complement of the platelet ADP receptors is essential for normal platelet secretion and that some patients with the common, ill-defined diagnosis of PSD are actually heterozygous for the defect.
Am Heart Assoc